Several other research firms also recently issued reports on NBIX. BidaskClub raised Neurocrine Biosciences from a buy rating to a strong-buy rating in a report on Wednesday, January 31st. Oppenheimer set a $100.00 price objective on Neurocrine Biosciences and gave the stock a buy rating in a report on Wednesday. Barclays reaffirmed an overweight rating and set a $100.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday. JPMorgan Chase & Co. upped their price objective on Neurocrine Biosciences from $79.00 to $100.00 and gave the stock an overweight rating in a report on Wednesday. Finally, Needham & Company LLC upped their price objective on Neurocrine Biosciences to $95.00 and gave the stock a buy rating in a report on Tuesday, January 16th. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Buy and a consensus target price of $88.79.
Neurocrine Biosciences (NASDAQ NBIX) opened at $85.25 on Wednesday. Neurocrine Biosciences has a 1-year low of $39.21 and a 1-year high of $91.82. The company has a quick ratio of 14.37, a current ratio of 10.20 and a debt-to-equity ratio of 0.99.
In other news, insider Dimitri E. Grigoriadis sold 86,368 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $78.32, for a total value of $6,764,341.76. Following the transaction, the insider now owns 154,717 shares of the company’s stock, valued at approximately $12,117,435.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Kevin Charles Gorman sold 105,983 shares of the stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $80.25, for a total value of $8,505,135.75. Following the completion of the transaction, the chief executive officer now directly owns 339,482 shares in the company, valued at approximately $27,243,430.50. The disclosure for this sale can be found here. In the last three months, insiders sold 337,950 shares of company stock worth $26,613,876. 4.80% of the stock is currently owned by company insiders.
Several hedge funds have recently bought and sold shares of NBIX. Perceptive Advisors LLC raised its stake in Neurocrine Biosciences by 33.9% during the 3rd quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock worth $293,629,000 after buying an additional 1,214,000 shares during the period. American Century Companies Inc. raised its stake in Neurocrine Biosciences by 1,257.3% during the 4th quarter. American Century Companies Inc. now owns 490,648 shares of the company’s stock worth $38,069,000 after buying an additional 454,500 shares during the period. Millennium Management LLC raised its stake in Neurocrine Biosciences by 357.3% during the 4th quarter. Millennium Management LLC now owns 534,566 shares of the company’s stock worth $41,477,000 after buying an additional 417,661 shares during the period. Renaissance Technologies LLC acquired a new stake in Neurocrine Biosciences during the 4th quarter worth $30,046,000. Finally, Allianz Asset Management GmbH raised its stake in Neurocrine Biosciences by 773.4% during the 4th quarter. Allianz Asset Management GmbH now owns 350,325 shares of the company’s stock worth $27,182,000 after buying an additional 310,214 shares during the period.
ILLEGAL ACTIVITY WARNING: “Neurocrine Biosciences (NBIX) Given New $97.00 Price Target at Deutsche Bank” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2018/02/18/neurocrine-biosciences-nbix-given-new-97-00-price-target-at-deutsche-bank.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.